PARP1 and cancer: To evaluate if the efficacy of BETi and PARPi correlated in cancer cells with PALB2 alterations, we examined the efficacy of BETi JQ1 and two PARP inhibitors olaparib and talazoparib across 43 PALB2 altered 763 non-altered human cancer cell lines [25] with overlapping drug response data available from the Genomics of Drug Sensitivity in Cancer Project (GDSC2) (https://www.cancerrxgene.org) [26].